ACMELAB Stock Overview
Manufactures, markets, and distributes generic pharmaceuticals formulation products in Bangladesh.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
The ACME Laboratories Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳71.40 |
| 52 Week High | ৳85.70 |
| 52 Week Low | ৳62.60 |
| Beta | 0.055 |
| 11 Month Change | 7.37% |
| 3 Month Change | 5.78% |
| 1 Year Change | -16.10% |
| 33 Year Change | -5.18% |
| 5 Year Change | -0.70% |
| Change since IPO | -36.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACMELAB | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | -2.1% | -0.5% | -0.5% |
| 1Y | -16.1% | -18.2% | -20.4% |
Return vs Industry: ACMELAB exceeded the BD Pharmaceuticals industry which returned -19.5% over the past year.
Return vs Market: ACMELAB exceeded the BD Market which returned -21.5% over the past year.
Price Volatility
| ACMELAB volatility | |
|---|---|
| ACMELAB Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in BD Market | 7.4% |
| 10% least volatile stocks in BD Market | 3.6% |
Stable Share Price: ACMELAB has not had significant price volatility in the past 3 months.
Volatility Over Time: ACMELAB's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 8,816 | Mizanur Sinha | www.acmeglobal.com |
The ACME Laboratories Ltd. manufactures, markets, and distributes generic pharmaceuticals formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care, gastrointestinal, gynaecological, hand sanitizers, hormones and steroid, infusion products, musculoskeletal, nasal preparation, respiratory, sex stimulants, skin care, urogenital, and vitamins and minerals. It also provides ayurvedic, and herbal and nutraceutical products.
The ACME Laboratories Ltd. Fundamentals Summary
| ACMELAB fundamental statistics | |
|---|---|
| Market cap | ৳15.11b |
| Earnings (TTM) | ৳2.42b |
| Revenue (TTM) | ৳30.81b |
6.2x
P/E Ratio0.5x
P/S RatioIs ACMELAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACMELAB income statement (TTM) | |
|---|---|
| Revenue | ৳30.81b |
| Cost of Revenue | ৳18.11b |
| Gross Profit | ৳12.71b |
| Other Expenses | ৳10.29b |
| Earnings | ৳2.42b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 11.44 |
| Gross Margin | 41.24% |
| Net Profit Margin | 7.86% |
| Debt/Equity Ratio | 93.6% |
How did ACMELAB perform over the long term?
See historical performance and comparison